BetterLife Pharma CEO Ahmad Doroudian joined Steve Darling from Proactive to share news the company has successfully completed the Phase 1 portion of the Phase 1-2 randomized placebo-controlled trial in COVID-19 patients with BetterLife’s inhaled interferon alpha-2b product, AP-003.
Dorourdian telling Proactive, Eighteen healthy subjects were enrolled in the Phase 1 portion of the IN2COVID trial. AP-003 demonstrated excellent safety and tolerability profile and no serious adverse events were observed. The company has now started a Phase 2 clinical trial for AP—003.